35 results about "Amyloid Depositions" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.

A system and method for performing virtual birefringence imaging and virtual staining (e.g., Congo red) of label-free human tissue is disclosed to show that a single trained neural network can rapidly transform autofluorescence images of label-free tissue into brightfield and polarized microscopy images, matching their histochemically-stained versions. Blind testing with quantitative metrics and pathologist evaluations on cardiac tissue showed that the virtually stained polarization and brightfield images highlight amyloid patterns in a consistent manner, mitigating challenges due to variations in chemical staining quality and manual imaging processes in the clinical workflow.

It is provided an anti-Aβ34 antibody and its use for diagnosing Alzheimer's disease in a patient, comprising obtaining a sample from the patient, detecting the level of Aβ34 in the sample by contacting the sample with the anti-Aβ34 antibody and detecting binding between Aβ34 and the antibody, and diagnosing the patient with Alzheimer's disease when the presence of Aβ34 in the sample is detected, alone or in combination with detecting an amyloid deposition marker such as Aβ42 and determining the ratio of Aβ34 / Aβ42.

Provided herein are antibodies that selectively bind N3pGlu Amyloid Beta peptide and their use in treating conditions or diseases characterized by deposition of Amyloid Beta.

The present disclosure provides methods and compositions for treating progeria or neurodegenerative diseases, particularly neurodegenerative diseases associated with amyloid deposition and neuronal death, such as Alzheimer's disease. Accordingly, aspects of the present disclosure relate to methods for treating progeria in a subject in need thereof, comprising administering to the subject a TERT-activating therapeutic agent. Other aspects relate to methods for treating a neurodegenerative disease in a subject, comprising administering to the subject a TERT-activating therapeutic agent.

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ, Abeta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide and an alpha-synuclein peptide.

The invention discloses a stem cell-negative hydrogen ion compound preparation for treating Alzheimer's disease, and belongs to the technical field of biomedicine, the compound preparation comprises stem cells, a negative hydrogen ion donor, piceatannol glucoside and a pharmaceutically acceptable carrier. Wherein the concentration of the stem cells is 1 * 10 < 6 >-1 * 10 < 8 > / mL, the concentration of the negative hydrogen ion donor is 25-45mg / mL, and the concentration of piceatannol glucoside is 4-8mu g / mL. The composite preparation integrates neural restoration, anti-inflammatory and immunoregulation functions of stem cells, an efficient antioxidant protection effect of a negative hydrogen ion donor and synergistic interaction and safety guarantee effects of piceatannol glucoside. Animal experiments prove that the composite preparation can significantly improve cognitive impairment of Alzheimer's disease model rats and relieve neuroinflammation, oxidative stress and beta-amyloid protein deposition through synergistic anti-inflammatory, anti-oxidation and neuroprotection mechanisms.

The present invention provides a composition and a method for treating a disease associated with amyloid deposits of Aβ in a patient's brain, such as Alzheimer's disease. Such a method involves administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of an antibody against Aβ. The immunogenic fragment comprises a linear or polyvalent peptide of Aβ. The pharmaceutical composition comprises an immunogenic fragment chemically linked to a carrier molecule that can be administered together with an ajuvant.

Targeted contrast agents are provided for MRI of amyloid deposition.

The present invention provides a therapeutic method and pharmaceutical composition that are effective in removing existing amyloid deposits and improve the prognosis of ALA patients. The present invention relates to methods and pharmaceutical compositions for treating amyloid deposition diseases using chimeric (e.g., mouse-human) antibodies, including methods for treating amyloid deposition diseases, including cardiac involvement, by administering pharmaceutical compositions containing chimeric anti-amyloid fibril antibodies, which can improve myocardial function in patients diagnosed with light chain amyloidosis (ALA) including cardiac involvement, within three weeks of treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to a novel application of indole-3-methanol or dimer 3, 3 '-diindolylmethane thereof in preparation of medicines for treating muscle degenerative diseases. According to the indole-3-carbinol and the dimer 3, 3 '-diindolylmethane thereof, muscle function decline is obviously delayed, a myofibril structure and a mitochondrial form are protected, and amyloid protein deposition and accumulation are reduced, so that the indole-3-carbinol and the dimer 3, 3'-diindolylmethane thereof play a good role in treating muscle decline related diseases such as sarcopenia and inclusion body myositis. The compound is natural in source and high in safety, can be applied to prevention and treatment of the muscle diseases in forms of oral administration, dietary supplements or pharmaceutical preparations and the like, and has a good industrial application prospect.

One aspect relates to a method for providing information for predicting a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and / or a positron emission tomography (PET)-positive risk group for amyloid β deposition, based on a European population-East Asian data. According to one aspect, the method makes it possible to accurately predict a risk group for developing Alzheimer's disease dementia or a risk group for early onset of Alzheimer's symptoms, or a risk group for developing amnestic mild cognitive impairment and / or a positron emission tomography (PET)-positive risk group for amyloid β deposition by using only at least 12 single-nucleotide polymorphisms, and the ability to predict the risk groups is further enhanced when up to and at most 80 additional single-nucleotide polymorphisms are used. In addition, the method further includes identifying age, sex, years of education, and APOE genotype as indicators, and thus the ability to predict the risk groups is further enhanced, and the risk groups can be predicted at an early stage with high accuracy.

Amyloid deposition is considered a viable biomarker for Alzheimer's disease which is expensive and less used modality to study amyloid spatial distribution in brain. The present disclosure addresses problems of conventional approaches which exhibit trade-off between performance and mode collapse. This disclosure provides a system and method for subject-specific amyloid position emission tomography (PET) translation using conditioned diffusion-based generative model. The present disclosure discloses an architecture for synthesizing subject-specific amyloid images with a diffusion model. First effectiveness of a relationship between Fluorodeoxyglucose (FDG) and amyloid PET images is identified. Further, a framework is provided to synthesize Amyloid PET by utilizing its connection to FDG PET of same subject and cross-subject trends in amyloid deposition by incorporating age, gender and disease status information in learning process. In the other words, a diffusion model inspired image translation is provided to synthesize Amyloid PET from FDG PET and cross-subject amyloid deposition patterns.

The present application relates to the technical field of Congo red derivative photocatalytic probe application, and particularly relates to a Congo red derivative photocatalytic probe, a preparation method and a use method thereof, comprising a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arene, the arene represents an aromatic heterocycle, and the aromatic heterocycle is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the present application can specifically label amyloid plaques in AD brain tissue slices, the binding affinity is significantly improved (Kd of Aβ 1‑40 The Congo red derivative photocatalytic probe can reveal the molecular heterogeneity of amyloid deposition and the key regulatory role of the mitochondrial autophagy-lysosome axis, provide a new tool for AD pathological mechanism research, support proteomic analysis and pathological mechanism analysis across brain regions (hippocampus / cortex), and protect the molecular structure and application in the research of neurodegenerative diseases.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses preparation and application of a sixteen-component medicine-food homologous prescription for treating Alzheimer's disease and depression through intelligence development and depression, and the preparation method comprises the following steps: S1, weighing the medicinal materials according to the prescription dosage, cleaning, selecting, drying and crushing to 50-100 meshes; s2, adding water into the medicinal materials, decocting for 1-3 times, decocting for 0.5-2 hours each time, combining filtrates at 60 DEG C, and concentrating until the relative density is 1.10-1.30, wherein the amount of added water is 5-15 times of the weight of the medicinal materials; s3, treating the concentrated solution by an alcohol precipitation method, standing, and recovering ethanol to obtain an extract; s4, mixing the extract with auxiliary materials to prepare one of granules, capsules or tablets; according to the traditional Chinese medicine composition disclosed by the invention, through a multi-target synergistic effect, cognitive dysfunction and mood disorder of patients with senile dementia and depression are remarkably improved. The tonifying medicinal materials such as the astragalus membranaceus and the rhizoma polygonati in the formula can enhance cerebral blood flow, inhibit beta amyloid protein deposition and tau protein phosphorylation and delay neurodegenerative diseases.

The present disclosure provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA and, in some cases, the amount of APP protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom or sign of a neurodegenerative disease or disorder associated with APP. Such symptoms and markers include cognitive impairment (including memory and language skill decline), behavioral and psychological symptoms (such as emotional desert and lack of motivation), gait disorders, seizures, progressive dementia, and abnormal amyloid deposition.

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in treatment of amyloidosis. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating amyloidosis; and / or (ii) preparation of drugs for alleviating or reversing amyloid deposition. The invention also provides a method for reducing or reversing amyloid protein deposition by using the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof, or the pharmaceutical composition, and a method for preventing and / or treating amyloidosis. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose of continuously obtaining clinical deep remission treatment for patients with recurrent and refractory amyloidosis.

The invention relates to the technical field of application of Congo red derivative photocatalytic probes, in particular to a Congo red derivative photocatalytic probe as well as a preparation method and a use method thereof.The Congo red derivative photocatalytic probe comprises a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arenes, arene represents a heteroaromatic ring, and the heteroaromatic ring is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the invention can specifically mark amyloid plaques in AD brain tissue slices, the binding affinity is remarkably improved (Kd of Abeta1-40 is equal to 0.07 mu m), the molecular heterogeneity of amyloid deposition and the key regulation and control effect of mitochondrial autophagy-lysosomal axis are disclosed, a new tool is provided for AD pathological mechanism research, and the Congo red derivative photocatalytic probe has a wide application prospect. And cross-brain region (hippocampus / cortex) proteome analysis and pathological mechanism analysis are supported, and the molecular structure and application in neurodegenerative disease research are simulated to be protected.

The invention relates to an A beta-PET brain template construction and quantitative analysis method based on deep learning, and the method comprises the steps: obtaining a PET image preprocessed by a normal participant, namely, an A beta-PET image; performing spatial registration to MNI152, and performing intensity normalization processing, data screening and average calculation to obtain a preliminary A beta-PET brain template image; the screened A beta-PET image is registered to a preliminary A beta-PET brain template image, and a final A beta-PET brain template image is obtained through intensity normalization processing, data screening, average calculation and smoothing processing; calculating a first quantitative parameter to construct a brain amyloid protein deposition data database; and performing spatial registration on the A beta-PET image to be analyzed to the final A beta-PET brain template image, dividing a brain region, calculating a second quantitative parameter, and comparing the second quantitative parameter with the brain amyloid protein deposition data database to complete quantitative analysis. The method has the beneficial effects that a normal A beta-PET brain template data database is established, a matched quantitative amyloid protein deposition analysis process is provided for clinical use, and the registration effect and the diagnosis and treatment efficiency are improved.

The present invention relates to isolated monoclonal antibodies or their antigen-binding moieties that specifically bind to amyloid fibrils and effectively promote the clearance of extracellular amyloid deposits from tissues in vivo, as well as to humanized antibodies having the same properties.

The present application relates to the technical field of medicine, and more particularly to a polypeptide for inhibiting and / or eliminating beta-amyloid aggregation and application thereof. The present application first develops a functional active polypeptide ANI-1 which can act on diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease from multiple targets, so as to effectively prevent and treat the diseases. The polypeptide ANI-1 of the present application has the functions of eliminating A beta aggregation, delaying behavioral decline caused by beta-amyloid toxicity (anti-paralysis, promoting movement), inhibiting neurogenic inflammation related to beta-amyloid deposition and enhancing antioxidant defense, has better overall efficacy and neuroprotective potential, and can provide a new idea for developing a multi-target drug for diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease.

The invention belongs to the technical field of biomedicine, and discloses application of a CHOP gene in preparation of a medicine for treating Alzheimer's disease. According to the application disclosed by the invention, the fact that the beta amyloid deposition of AD can be effectively relieved by knocking out or knocking down the CHOP gene is determined for the first time, neuroinflammation in the brain can be reduced, and the spatial learning and memory ability disorder of AD transgenic mice can be effectively improved. A new target spot is provided for AD treatment, clinical transformation value is achieved, and a preparation with the CHOP gene knocked out or knocked down can be used for preparing the medicine for treating the Alzheimer's disease.

This invention discloses a bicyclic compound, its intermediate, a preparation method, and its applications. Specifically, it discloses a compound as shown in Formula I, and its pharmaceutically acceptable salt or isotope. The compound of this invention exhibits good binding ability to amyloid protein, a short half-life, and good imaging effect. Furthermore, the compound of this invention can be used to prepare positron emission tomography (PET) agents and can be used for the early diagnosis of amyloid protein deposition-related diseases, such as Alzheimer's disease, and for monitoring the efficacy of drugs.

The invention discloses a computer-aided drug screening method, system and device based on an IAPP. The application proves that the SARS-CoV-2S / N protein is directly combined with the IAPP and promotes the pathological aggregation of the IAPP in a host body for the first time. It is found for the first time that new coronavirus infection induces activation of a pancreas islet microenvironment complement system, and pro-inflammatory factor release and endoplasmic reticulum stress synergistically aggravate beta cell function failure. Insulin secretion disorder caused by the fact that IAPP aggregation destroys the SNARE complex mediated insulin vesicle transportation process is found for the first time. The invention provides a brand new theory that the new coronavirus causes beta cell dysfunction by physically hijacking key functional proteins of a host, and discloses an age-dependent mechanism that the virus aggravates islet amyloid protein deposition in the elderly population. And a new theoretical basis and a treatment direction are provided for age-dependent management and viral metabolic disorder research of diabetes after epidemic.

The invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and particularly provides a diaryl piperazine compound capable of detecting neurodegenerative diseases and heart-related diseases and a derivative of the diaryl piperazine compound. The compound has high affinity to aggregated beta-folded proteins such as pathological beta-amyloid protein, immunoglobulin light chain aggregate, transthyretin aggregate and the like, and has a structure as shown in a general formula I. After being labeled by radionuclides, the compound and the derivative thereof can be used for nuclear medicine clinical diagnosis of patients with amyloid protein deposition characteristics including neurodegenerative diseases and heart amyloid protein diseases. Compound with structure as shown in general formula I: # imgabs0 #

The invention discloses an application of mesenchymal stem cell extracellular vesicles in preparation of a medicine for treating diseases caused by beta amyloid protein deposition, and provides a new application of the mesenchymal stem cell extracellular vesicles used for SD rat bone marrow in preparation of a medicine for treating A beta 25-35 infection. The toxicity caused by A beta 25-35 in pc12 cells is reduced by reasonably utilizing extracellular vesicles of SD rat bone marrow mesenchymal stem cells. Therefore, the toxicity of the PC12 is inhibited, and the PC12 is protected from deeper invasion. A new thought is provided for treatment of the Alzheimer's disease.

The invention belongs to the field of medicines for inhibiting Alzheimer's disease, and particularly relates to safflower seed oil for inhibiting Alzheimer's disease and a preparation method thereof. The invention specifically discloses an optimized moderate refining technology of safflower seed oil, and verification of a benign intervention effect of the optimized moderate refining technology on AD disease progression. Compared with the classic refining technology, the moderate refining can effectively reduce the loss of key fatty acid linoleic acid in the safflower seed oil and effectively improve the retention rate of trace accompanying substances such as sterol and vitamin E, and is superior to the traditional refining technology. The safflower seed oil obtained by moderate refining can effectively inhibit the progress of a double-transgenic Alzheimer's mouse in a multi-target and multi-mechanism manner, especially decrease the deposition amount of beta amyloid protein in brain tissues, increase the number of Nissl bodies in a cortex region of the brain tissues, and lower the peroxidation index in the brain tissues and serum, so as to inhibit the disease progression of the double-transgenic Alzheimer's mouse in a multi-target and multi-mechanism manner. The safflower seed oil obtained by moderate refining can be used for clinical treatment and adjuvant therapy of degenerative neuropathy, especially Alzheimer's disease.

To provide modified immunoglobulins for targeting amyloid deposits.SOLUTION: Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.SELECTED DRAWING: Figure 3

The Alzheimer's disease diagnosis method using PET-CT images according to the present application can include: a process of generating a standard brain CT template in MNI (Montreal Neurological Institute) space from a CT image calculated by a PET-CT device; a process of calculating a whole cortex volume of interest (VOI) of a plurality of sub-regions in which the deposition of beta amyloid is above a certain value in a cortex ROI (cortex ROI) region based on the above standard brain CT template; and a process of calculating a percentage unit of each of the above plurality of sub-regions based on the amyloid deposition rate (Standardized uptake value ratio, SUVR) of each of the above plurality of sub-regions. 18 F-florbetaben (FBB) 18 F-florbetaben (FBB) 18 F-flutemetamol (FMM) 18 F-flutemetamol (FMM)

The present invention provides a liposome composition ("ADx-001") comprising: a first phospholipid; a sterically hindered bulky excipient capable of stabilizing the liposome composition; a second phospholipid derivatized with the first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid derivatized with the second polymer, the second polymer being coupled to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be coupled to a fourth phospholipid.